# Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma

> **NCT00631631** · — · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 205 (actual)

## Conditions studied

- Osteosarcoma

## Interventions

- **DRUG:** Mifamurtide (L-MTP-PE)

## Key facts

- **NCT ID:** NCT00631631
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2014-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00631631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00631631, "Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00631631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*